Skip to content

Study · Animal study (in vivo) · mouse · 2022

1 result

Nicotinamide Mononucleotide Alleviates Cardiomyopathy Phenotypes Caused by Short-Chain Enoyl-Coa Hydratase 1 Deficiency.

Cai K, Wang F, Lu JQ, Shen AN, Zhao SM, Zang WD, Gui YH, Zhao JY

JACC. Basic to translational science25 Apr 2022Cited by 43 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Echs1 heterozygous knockout mice, NMN-mediated acetylation targeting suppressed cardiomyopathy phenotypes.

    In plain wordsIn mice with partial Echs1 loss, NMN-mediated acetylation targeting reduced cardiomyopathy features.

    Outcome
    DecreaseCardiomyopathy phenotypes
    Study

    mousen: not reported in source

    Echs1 heterozygous knockout mice
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nicotinamide mononucleotide-mediated acetylation targeting suppressed ECHS1 deficiency-induced cardiomyopathy phenotypes in Echs1 +/- mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.